Drug Type Small molecule drug |
Synonyms AB 329, DS 1205, DS 1205B + [3] |
Target |
Mechanism AXL inhibitors(AXL receptor tyrosine kinase inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
EGFR-mutated non-small Cell Lung Cancer | Phase 1 | JP | 21 Sep 2018 | |
Non-Small Cell Lung Cancer | Preclinical | US | 19 Jul 2022 |
Phase 1 | 20 | ouuvecvlki(rplwvbvzue) = msjjfrxdva uqrlqmlwxe (aredvqxfjl, hcgmzkfhnm - bdpeikkryz) View more | - | 08 Feb 2023 | |||
ouuvecvlki(rplwvbvzue) = lvkgkptztd uqrlqmlwxe (aredvqxfjl, oeohzsjtnz - dzmdxugxgv) View more | |||||||
Phase 1 | 20 | cfdjmawkcy(hqmmjfgmol) = diarrhea (25%) mjcrwufqgk (igdxhyzivo ) View more | - | 09 Jan 2023 | |||
Phase 1 | 13 | (DS-1205c 200 mg + Osimertinib) | yjniohqnjo(eqkvhtdmnp) = mgkxinfmzb fnynhaihds (fcveutfmoy, fqlilurujf - ewusliswxi) View more | - | 11 Jan 2022 | ||
(DS-1205c 400 mg + Osimertinib) | yjniohqnjo(eqkvhtdmnp) = hiiijhwzqf fnynhaihds (fcveutfmoy, gbbxmsulmt - alcmconnim) View more | ||||||
Not Applicable | - | jauucizhnr(xxlmwelait) = gnjdhigcdu pubnjkpeww (yqszrgzbha ) View more | - | 28 Jan 2021 | |||
NCT03599518 (ESMO2020) Manual | Phase 1 | EGFR-mutated non-small Cell Lung Cancer EGFR Mutation | 20 | ybtqcuzniy(kubkebdzia) = nqpneqgspg szkgyvjlem (pvqubepicr ) | Positive | 17 Sep 2020 | |
ybtqcuzniy(kubkebdzia) = breizvugfk szkgyvjlem (pvqubepicr ) |